Premium
Soluble epoxide hydrolase inhibitors are first in class therapeutic candidates for chronic and intractable pain in man and companion animals (1061.4)
Author(s) -
Inceoglu Bora
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1061.4
Subject(s) - epoxide hydrolase 2 , analgesic , medicine , chronic pain , clinical trial , neuropathic pain , pharmacology , enzyme , biology , physical therapy , biochemistry
Eicosis is founded with the goal of commercializing a first‐in‐class drug that inhibits soluble epoxide hydrolase (sEH) ‐ a master regulatory enzyme in the arachidonic acid cascade, a key biological pathway in the pathogenesis and treatment of many inflammation‐driven chronic diseases. Due to the pivotal role of sEH enzyme, Eicosis is in a position to target a multitude of therapeutic areas constituting unmet clinical needs. Our focus will be to develop a small molecule inhibitor of sEH to treat pain in humans and in companion animals. In spite of the availability of numerous types of analgesics, both human and companion animal pain are insufficiently treated leading to suffering and reduced quality of life. Recent estimates of global analgesic sales highlight these unmet clinical needs and a significant commercial opportunity, in particular for chronic and pharmaco‐resistant painful conditions. Three year goals are a) to have an IND‐ready drug candidate for a neuropathic pain clinical trial in humans, and b) to have a companion animal analgesic NDA. The long‐term vision is that Eicosis, in conjunction with strategic partners, will build a market‐dominating franchise focused on the arachidonic acid pathway; with multiple products on the market. Here we provide a synopsis of the technology and candidate sEH inhibitors to treat inflammatory and neuropathic pain in companion animal and human patients.